BIB ProShares Ultra Nasdaq Biotechnology

USD 51.31 0.00 0
Icon

ProShares Ultra Nasdaq Biotechnology (BIB) Stock Analysis and Price Targets

ETF | Trading--Leveraged Equity | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 51.31

0.00 (0.00)%

USD 0.10B

0.01M

N/A

N/A

Icon

BIB

ProShares Ultra Nasdaq Biotechnology (USD)
ETF | NSD
USD 51.31
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.10B

N/A

USD 51.31

ProShares Ultra Nasdaq Biotechnology (BIB) Stock Forecast

N/A

Based on the ProShares Ultra Nasdaq Biotechnology stock forecast from 0 analysts, the average analyst target price for ProShares Ultra Nasdaq Biotechnology is not available over the next 12 months. ProShares Ultra Nasdaq Biotechnology’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ProShares Ultra Nasdaq Biotechnology is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, ProShares Ultra Nasdaq Biotechnology’s stock price was USD 51.31. ProShares Ultra Nasdaq Biotechnology’s stock price has changed by -4.09% over the past week, -8.03% over the past month and -9.12% over the last year.

No recent analyst target price found for ProShares Ultra Nasdaq Biotechnology
No recent average analyst rating found for ProShares Ultra Nasdaq Biotechnology

Company Overview ProShares Ultra Nasdaq Biotechnology

The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified ...Read More

http://www.proshares.com

N/A

N/A

N/A

USD

USA

06/04/2010

NASDAQ Biotechnology TR USD

S&P 500 TR USD

0.95 %

Adjusted Closing Price for ProShares Ultra Nasdaq Biotechnology (BIB)

Loading...

Unadjusted Closing Price for ProShares Ultra Nasdaq Biotechnology (BIB)

Loading...

Share Trading Volume for ProShares Ultra Nasdaq Biotechnology Shares

Loading...

Compare Performance of ProShares Ultra Nasdaq Biotechnology Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BIB

Top Sectors

N/A

Top Regions

N/A

Valuation Growth & Performance

  • 0

  • S&P 500 TR USD

  • 3

  • 34.35

  • 0.00

  • -0.28

  • -4.89%

  • -13.79%

  • -0.95%

  • 0%

Stocks Similar To ProShares Ultra Nasdaq Biotechnology (Sector: Trading--Leveraged Equity )

Symbol Name Mer Price(Change) Market Cap
TQQQ
ProShares UltraPro QQQ 0.88 % 0.00 (0.00%) USD22.36B

ETFs Containing BIB

Symbol Name BIB's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About ProShares Ultra Nasdaq Biotechnology (BIB) Stock

Stock Target Advisor's fundamental analysis for ProShares Ultra Nasdaq Biotechnology's stock is Slightly Bearish.

BIB stock's dividend yield is 0.07%. Our analysis grades BIB stock's dividend yield at F. This means that BIB stock's dividend yield is above 50% of the stocks in the Trading--Leveraged Equity sector in the NSD exchange. Based on this BIB may be a average dividend stock for its sector.

Unfortunately we do not have enough data on BIB's stock to indicate what its average analyst target is.

BIB stock's Price/Earning ratio is 20.40. Our analysis grades BIB stock's Price / Earning ratio at A+. This means that BIB stock's Price/Earning ratio is above 0% of the stocks in the Trading--Leveraged Equity sector in the NSD exchange. Based on this BIB may be undervalued for its sector.

The last closing price of BIB's stock was USD 51.31.

The most recent market capitalization for BIB is USD 0.10B.

Unfortunately we do not have enough analyst data on BIB's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains ProShares Ultra Nasdaq Biotechnology's stock.

Sorry, we do not have any data on the number of employees for ProShares Ultra Nasdaq Biotechnology.

Sorry we do not have any infomation available on ProShares Ultra Nasdaq Biotechnology's address.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...